FDA Gives Clinical Trial Green Light on Drug to Treat Alzheimer’s Disease
Previous Studies Show Bryostatin Protects Against Alzheimer’s Protein, Rewires and Repairs Brain Damage
“We are very excited about the FDA’s agreement for BRNI to move forward with clinical trials,” said Dr.
Bryostatin was originally created as an anti-cancer chemotherapy. When BRNI scientists extensively tested PKC activators against Alzheimer’s disease models, they discovered the drug’s hidden potential to stop Alzheimer’s disease. Over the past six years, the drug has shown remarkable possibilities. In preclinical testing, BRNI scientists experimented with Bryostatin on three species of Alzheimer’s disease transgenic mice, each species based on different human Alzheimer’s disease genes. The test results revealed that Bryostatin, and a related class of drugs discovered at BRNI, can reduce the toxic Alzheimer’s disease protein A Beta, restore lost synapses, and protect against the loss of memory functions. In related preclinical testing, Bryostatin has been shown to enhance and restore memory by rewiring connections in the brain previously destroyed by stroke, head trauma, or aging itself.
The Phase II trials, slated to begin in approximately two to four months, will test these preclinical findings on human Alzheimer’s disease patients as well as controls, along with Bryostation’s effects on molecular targets in the human body, such as the signaling enzyme PKC. The drug’s side effects will also be carefully monitored using low doses that were previously found to be generally benign in human cancer patients.
“With the potential to not just treat symptoms, but also stop the causes, the Bryostatin trial on Alzheimer’s disease patients represents a new direction for the treatment of a disease with no current cure,” said Alkon. “And the timing is crucial because as many as 5.3 million people live with Alzheimer’s disease in
BRNI is the world’s only non-profit institute dedicated to the study of both human memory and diseases of memory. Its primary mission is to accelerate the transfer of neurological discoveries from the lab to the doctor’s office where it can benefit patients who suffer from neurological and psychiatric diseases.
BRNI is operated in alliance with
SOURCE Blanchette Rockefeller Neurosciences Institute